Background: Few population-based studies have investigated the premalignant
Materials and Methods

Study Population
We carried out the present survey from August 2006 to December 2009 in Beijing, where there are 18 districts (four urban ones, four suburban ones and ten outer suburbs). On the basis of data from the 2005 census published by the National Bureau of Statistics of China, our representative sample of the adult female population of Beijing was stratified by age and regional distribution using a multi-stage cluster sampling method. First, according to the proportion of each district's population, 5-8 communities were randomly selected from each district.
Second, one neighborhood was randomly chosen from each community. Finally, from the lists provided by local neighborhoods, a final random sample of 50 women per neighborhood was derived. After selecting randomized samples of the population, door-to-door visits were made to recruit these women to their local Maternal and Child Health Hospitals. If the recruited number was bigger than the sample required, another random sampling was performed on this basis.
If the recruited number was smaller than the sample required, the number from each neighborhood was further increased through random sampling. On the basis of the age ratios of the 2005 census, the study strove to enroll
HPV Detection and typing
Additional cells were obtained with a dacron swab inside endocervical canal and from entire circumference of ectocervix for HPV testing. The second-generation hybrid capture (HC-Ⅱ) test (Digen Corporation, US) using the high-risk probe cocktail was performed for all subjects in the study. Quantitative detection of HPV DNA was evaluated at the molecular level by detections of gene hybridization-chemiluminescence-signal amplification technology. The high-risk probe cocktail, which detects the HPV types 16, 18, 31, 33, 35 , 39, 45, 51, 52, 56, 58, 59, and 68, was used based on the manufacturer's instructions. A positive result referred to a patient who was positive for one or more of the thirteen high-risk HPV types included. Samples were considered positive if they attained or exceeded the FDA approved threshold of HPV DNA 1.0 pg /ml, which corresponded to 1.0 relative light unit (RLU). Infection with low-risk HPV types was not evaluated.
DNA was extracted from the paraffin embedded tissue of cervical biopsies and amplified by PCR using HPV DNA primers. The overall presence of HPV 
Statistical Analysis
Statistical analysis was performed using SPSS version 13.0 software.
Descriptive analysis was made of the demographic data. The various charactersistics of the cervical lesion prevalence, positive with high-risk HPV, were determined using the prevalence rate. Odd Ratio (OR) with 95% confidence interval (CI) was used to estimate relative risk using unconditional, (1,219/6,339) of women have experienced cervical cytology detection.
Cytology results
All of the study subjects underwent cervical cytology tests. 
Cervical lesion prevalence
Women with pathology results CIN I and CIN II + were collectively referred to as positive pathology and diagnosed as having cervical lesion. 607 positive cytology cases underwent cervical biopsy and pathologically diagnosed with 374 positive pathology cases. 115 randomly sampled negative cytology women had pathological diagnosis as control, and no cases suffered cervical lesion.
The prevalence of cervical lesion was 5.9%, CIN I was 4.7%, and CIN II + was 1.2%. Adjusted with age, the estimated overall prevalence of cervical lesion in the population of Beijing was 5.8%. Table 1 presents the cervical lesion distribution of the subjects, the overall prevalence, age-adjusted OR and 95%
CI of each cytological category.
High-risk HPV and HPV subtype
6,339 women provided cervical cell samples, 154 cases' specimens for HC-Ⅱ test were not eligible, leaving 6,185 valid high-risk HPV results (with 615 positive cases). High-risk HPV was 41.2% in the cytology positive group and 6.6% in the cytology negative group; 50.5% in the cervical lesion group, 7.4% in the no-lesion group. Adjusted with age, the estimated overall prevalence of high-risk HPV was 9.9% among the population of Beijing.
Higher grade cervical lesions were associated with greater high-risk HPV 
Discussion
National-level cancer mortality data is sparse in China. The incidence rate
of cervical cancer appears to be varied in different geographical areas and the age-specific curves of the incidence rate appear to be varied (13, (17) (18) (19) This is the first population-based study to investigate the prevalence rate of cervical lesion and high-risk HPV infection among a large sample in Beijing or even in China. With the support of the government, the Chinese women have attached greater importance to cervical cancer. More than 99% participation in all components of the study was attained, assuring the representativeness of the study population and allowing for population-wide estimates. In Beijing, the age-adjusted prevalence rate of cervical lesion is 5.8%, which is higher than the known cervical lesion prevalence in the developed countries (2,20,21). More severe cervical cytology abnormality was associated with higher prevalence of cervical lesion. The increasingly severe diagnostic categories were strongly associated with increasing overall detection of high-risk HPV in the lesion, and increasing OR. The HPV DNA load ＜100 pg /ml was considered as low-load while ≥100 pg /ml was considered as high-load, the HPV DNA load had obvious relevance with cervical lesion in accordance with other results (22 The age pattern of HPV prevalence also differs somewhat from one country to another. The predominant pattern features an early peak soon after the start of sexual intercourse (28), followed by lower levels of HPV positivity in middle age (28, 29) . In studies from sub-Saharan Africa (30), the prevalence of HPV declined with age. In our survey, high-risk HPV prevalence was highest in women aged 30-34 years and declined thereafter, which is similar to some 
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